CIA
GBT

Capital Impact Advisors’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Capital Impact Advisors’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-24,167
Closed -$772K – 238
2022
Q2 		$772K Sell
24,167
-4,834
-17% -$142K 0.71% 29
2022
Q1 		$1M Buy
29,001
+6,540
+29% +$196K 0.73% 36
2021
Q4 		$657K Buy
+22,461
New +$696K 0.45% 69
2020
Q4 		– Sell
-26,362
Closed -$1.45M – 127
2020
Q3 		$1.45M Sell
26,362
-5,000
-16% -$318K 0.43% 92
2020
Q2 		$1.98M Sell
31,362
-18,268
-37% -$1.25M 0.66% 74
2020
Q1 		$2.54M Buy
49,630
+1,475
+3% +$98.8K 1.07% 27
2019
Q4 		$3.83M Hold
48,155
– – 1.35% 13
2019
Q3 		$2.37M Buy
48,155
+8,289
+21% +$432K 0.9% 23
2019
Q2 		$2.15M Sell
39,866
-11,686
-23% -$672K 0.79% 41
2019
Q1 		$2.06M Hold
51,552
– – 0.91% 27
2018
Q4 		$2.06M Hold
51,552
– – 0.88% 28
2018
Q3 		$1.97M Buy
51,552
+3,017
+6% +$134K 0.67% 67
2018
Q2 		$2.3M Buy
48,535
+18,966
+64% +$864K 0.85% 29
2018
Q1 		$1.43M Buy
+29,569
New +$1.65M 0.59% 86

Other funds holding GBT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital Impact Advisors's GBT Position: Q3 2022 in Review

Capital Impact Advisors sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2022, closing a stake of 24,167 shares — an estimated $772K sold.

Capital Impact Advisors first reported a position in GBT in Q1 2018 and held it in 14 quarters. The position peaked at $3.83M in Q4 2019. 247 funds tracked by Wall St. Rank hold GBT as of Q3 2022.

  • Capital Impact Advisors reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2022 after selling out during the quarter.
  • Capital Impact Advisors sold 24,167 Global Blood Therapeutics, Inc. shares in Q3 2022, an estimated $772K.
  • Capital Impact Advisors first reported a position in Global Blood Therapeutics, Inc. in Q1 2018 and held it in 14 quarters.
  • Capital Impact Advisors's Global Blood Therapeutics, Inc. position peaked at $3.83M in Q4 2019.
  • 247 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2022.

Based on Capital Impact Advisors's 13F filing for Q3 2022, filed 22 Nov 2022.